BUZZ-Viatris 的焦虑症药物在后期试验中达到主要目标;股价上涨

Reuters
Oct 09, 2024

((自动化翻译由路透提供,请见免责声明 ))

路透10月9日 - **制药商Viatris 股价上涨1%,报11.44美元

** 该公司的药物Effexor (link) 在治疗日本成年患者广泛性焦虑症的后期研究中达到了主要和次要目标(GAD)

** 研究显示,在治疗焦虑症 8 周时,艾菲克索的疗效优于安慰剂

** 艾菲克索的耐受性总体良好,与已知的非日本患者的安全状况一致

** 该公司计划于 2025 年向日本监管机构提交艾菲克索的申请

** 艾菲克索在 80 多个国家被批准用于治疗 GAD

** 包括本交易日的走势在内,该股今年累计上涨 5.2

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10